Article
Enhertu's groundbreaking HER2-low breast cancer nod could come this year as AZ, Daiichi seek ambitious approval
Rating:
0.0
Views:
53
Likes:
1
Library:
1
After winning a standing ovation at the recent American Society of Clinical Oncology meeting, Enhertu's HER2-low breast cancer data are now getting the VIP treatment at the FDA. | After winning a standing ovation at the recent ASCO event, Enhertu's HER2-low breast cancer data are now getting the VIP treatment at the FDA. And AstraZeneca and Daiichi Sankyo are targeting an ambitiously broad patient population.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value